PARP10 and ovarian carcinoma: To this end, we quantified the percentage of the mitotic population in HeLa (ovarian cancer), A375 (melanoma), U2OS (osteosarcoma), T47D (breast cancer) and HepG2 (hepatocellular carcinoma) cells treated with the PARP10 specific inhibitor OUL35 [47].